Medicare can pay for obesity drugs like Wegovy in certain heart patients
Medicare can pay for the popular weight-loss drug Wegovy — as long as the patients using it also have heart disease and need to reduce the risk of future heart attacks, strokes and other serious problems, federal officials said Thursday.
The Centers for Medicare & Medicaid Services issued new guidance that says Medicare Part D drug benefit plans — which are offered through private insurers — could cover anti-obesity drugs that are approved for an additional use.
The move could pave the way for thousands of new prescriptions, resulting in billions of dollars in increased spending, analysts have said.
In practice, the guidance opens the door to wider coverage of Wegovy, the brand name of Novo Nordisk’s obesity medication semaglutide. The U.S. Food and Drug Administration this month approved a label change that allows Wegovy to be used to reduce the risk of cardiovascular events in people who are overweight or have obesity and also have existing heart disease.
Related articles
What a blast to work at NASA. Space agency is sky
WASHINGTON (AP) — Exploring the cosmos makes for happy employees, federal workers like to work from2024-05-22Te reo Māori: Govt seeks to halt extra pay for public servants fluent in the language
File photo. Public Service Minister Nicola Willis told RNZ she would ask for advice on how the gover2024-05-22Couple waits for categorisation of flood
Glenn Whittington points to water line during flooding. Photo: RNZ / Luka Forman2024-05-22'Unusually cool March': Cold but clear weather for Easter weekend
Most of the South Island had single-digit temperatures Friday morning. Photo: 123rf2024-05-22Dame Judi Dench's tears as she receives Sycamore Gap tree seedling at Chelsea Flower Show
Dame Judi Dench shed a tear yesterday after being presented with a seedling from the famous Sycamore2024-05-22Water meter charges planned for Masterton
Water meters are planned to be used for Masterton water charges as of July 2025. Photo: LDR / Emily2024-05-22
atest comment